|
Name |
(1Z,6R,11R,13R,14S,15S,16R,19E,23R,27R)-23-acetyl-27-hydroxy-9,15-dimethylspiro[4,12,17,24-tetraoxapentacyclo[21.3.1.113,16.06,11.06,15]octacosa-1,9,19-triene-14,2'-oxirane]-3,18-dione
|
Molecular Formula | C29H36O9 | |
IUPAC Name* |
(1Z,6R,11R,13R,14S,15S,16R,19E,23R,27R)-23-acetyl-27-hydroxy-9,15-dimethylspiro[4,12,17,24-tetraoxapentacyclo[21.3.1.113,16.06,11.06,15]octacosa-1,9,19-triene-14,2'-oxirane]-3,18-dione
|
|
SMILES |
CC1=C[C@@H]2[C@@]3(CC1)COC(=O)/C=C\4/CCO[C@@]([C@@H]4O)(CC/C=C/C(=O)O[C@H]5[C@]3([C@]6(CO6)[C@@H](C5)O2)C)C(=O)C
|
|
InChI |
InChI=1S/C29H36O9/c1-17-7-10-27-15-34-24(32)13-19-8-11-35-28(18(2)30,25(19)33)9-5-4-6-23(31)38-20-14-22(37-21(27)12-17)29(16-36-29)26(20,27)3/h4,6,12-13,20-22,25,33H,5,7-11,14-16H2,1-3H3/b6-4+,19-13-/t20-,21-,22-,25-,26-,27-,28+,29+/m1/s1
|
|
InChIKey |
LXIQXFWXXPJPEE-OICCJBEUSA-N
|
|
Synonyms |
mytoxin B; 105049-15-8
|
|
CAS | NA | |
PubChem CID | 156597133 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 528.6 | ALogp: | 1.4 |
HBD: | 1 | HBA: | 9 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 121.0 | Aromatic Rings: | 6 |
Heavy Atoms: | 38 | QED Weighted: | 0.31 |
Caco-2 Permeability: | -5.333 | MDCK Permeability: | 0.00001450 |
Pgp-inhibitor: | 0.031 | Pgp-substrate: | 0.957 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.868 |
30% Bioavailability (F30%): | 0.91 |
Blood-Brain-Barrier Penetration (BBB): | 0.722 | Plasma Protein Binding (PPB): | 60.08% |
Volume Distribution (VD): | 0.992 | Fu: | 26.74% |
CYP1A2-inhibitor: | 0.005 | CYP1A2-substrate: | 0.852 |
CYP2C19-inhibitor: | 0.114 | CYP2C19-substrate: | 0.482 |
CYP2C9-inhibitor: | 0.032 | CYP2C9-substrate: | 0.018 |
CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.038 |
CYP3A4-inhibitor: | 0.708 | CYP3A4-substrate: | 0.85 |
Clearance (CL): | 10.623 | Half-life (T1/2): | 0.674 |
hERG Blockers: | 0.019 | Human Hepatotoxicity (H-HT): | 0.425 |
Drug-inuced Liver Injury (DILI): | 0.777 | AMES Toxicity: | 0.982 |
Rat Oral Acute Toxicity: | 0.957 | Maximum Recommended Daily Dose: | 0.916 |
Skin Sensitization: | 0.32 | Carcinogencity: | 0.714 |
Eye Corrosion: | 0.168 | Eye Irritation: | 0.075 |
Respiratory Toxicity: | 0.092 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002026 | 0.886 | D06XHC | 0.264 | ||||
ENC004392 | 0.683 | D0Q4SD | 0.258 | ||||
ENC004393 | 0.669 | D0EP0C | 0.255 | ||||
ENC004254 | 0.646 | D04GJN | 0.252 | ||||
ENC002240 | 0.606 | D09WYX | 0.244 | ||||
ENC003126 | 0.595 | D0I2SD | 0.243 | ||||
ENC004774 | 0.585 | D0V2JK | 0.241 | ||||
ENC004775 | 0.582 | D06AEO | 0.238 | ||||
ENC002696 | 0.580 | D0P0HT | 0.236 | ||||
ENC003943 | 0.574 | D0K7HU | 0.236 |